Table 1 Clinocopathologic information of the cases
SRI | SRI % | IRI | IRI % | LRI | LRI % | |
|---|---|---|---|---|---|---|
Number of cases | 41 | 57 | 39 | |||
Age at diagnosis | ||||||
<50 | 19 | 46.3 | 20 | 35.1 | 18 | 46.2 |
≥50 | 22 | 53.7 | 37 | 64.9 | 21 | 53.8 |
Histologic type | ||||||
ductal | 24 | 58.5 | 36 | 63.2 | 16 | 41 |
lobular | 17 | 41.5 | 19 | 33.3 | 23 | 59 |
other | 0 | 0 | 1 | 1.8 | 0 | 0 |
Grade | ||||||
G1 | 4 | 9.8 | 7 | 12.3 | 8 | 20.5 |
G2 | 22 | 53.7 | 35 | 61.4 | 26 | 66.7 |
G3 | 15 | 36.6 | 15 | 26.3 | 5 | 12.8 |
Estrogen receptor status | ||||||
negative | 18 | 46.2 | 18 | 32.1 | 12 | 31.6 |
positive | 21 | 53.8 | 38 | 67.9 | 26 | 68.4 |
Progesterone receptor status | ||||||
negative | 17 | 43.6 | 17 | 30.4 | 8 | 21.1 |
positive | 22 | 56.4 | 39 | 69.6 | 30 | 78.9 |
Ki67 | ||||||
≤20% | 22 | 57.9 | 45 | 84.9 | 29 | 74.4 |
>20% | 16 | 42.1 | 8 | 15.1 | 3 | 7.7 |
HER2 status | ||||||
negative | 27 | 69.2 | 51 | 89.5 | 38 | 97.4 |
positive | 12 | 30.8 | 5 | 10.5 | 1 | 2.6 |
Size of primary tumor | ||||||
≤20 mm | 14 | 35 | 28 | 50 | 24 | 61.5 |
>20 mm | 26 | 65 | 28 | 50 | 15 | 38.5 |
Lymph node status at diagnosis | ||||||
no metastasis | 16 | 39 | 35 | 61.4 | 22 | 61.1 |
metastasis | 25 | 61 | 22 | 38.6 | 14 | 38.9 |
Tumour subtype | ||||||
HR+HER2- | 21 | 53.8 | 42 | 75.0 | 33 | 86.8 |
HR+HER2+ | 4 | 10.3 | 6 | 10.7 | 0 | 0 |
HR-HER2+ | 7 | 17.9 | 0 | 0 | 0 | 0 |
TNBC | 7 | 17.9 | 8 | 14.3 | 5 | 13.2 |